A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs

NCT04401761 · clinicaltrials.gov ↗

COMPLETED

Status

3189

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease
Peripheral Artery Disease

Interventions

DRUG: Rivaroxaban (BAY59-7939, Xarelto)
DRUG: Acetylsalicylic acid

Sponsor

Bayer